[Sobrerol as expectorant in patients with stable chronic respiratory tract infections. A controlled study].
A randomized double-blind crossover study compared the clinical effectiveness of 14-day treatment with 400 mg/day of sobrerol and placebo in 23 patients with stable chronic bronchial disease. In a further open trial phase all patients received 2.0 g glyceringuaiacol per day. During the 9-week trial, subjective symptoms and findings were recorded by numerical code, side-effects listed, pulmonary function tests performed and sputum physical characteristics determined on a weekly basis. Data was statistically analyzed using an analysis of variance adapted from HILLS and ARMITAGE, the Wilcoxon matched-pairs signed-ranks test, the paired t-test and the %2 test. Both subjective assessment of overall clinical efficacy and statistical analysis of the above factors failed to show any significant advantage of sobrerol over placebo. Sputum physical characteristics failed to reveal a significant difference between sobrerol and placebo, with the exception of a temporary reduction in sputum volume (p less than 0.05) on the fourth day of therapy with sobrerol. Similarly, 2.0 g glyceringuaiacol for 14 days failed to influence subjective symptoms, pulmonary function tests or sputum physical characteristics. In conclusion, sobrerol is a further example of an expectorant lacking evidence of clinical effectiveness in the management of bronchial secretions in patients with stable chronic bronchial disease.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006140:Guaifenesin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013729:Terpenes / Q000008:administration & dosage / Q000627:therapeutic use*
D005100:Expectorants; D013729:Terpenes; D006140:Guaifenesin; C003316:sobrerol
Sobrerol als Expektorans bei Patienten mit stabilen chronischen Atemwegerkrankungen. Eine kontrollierte Studie.